<DOC>
	<DOCNO>NCT01256086</DOCNO>
	<brief_summary>The purpose study estimate relative potency bronchoprotective effect formoterol Novolizer 12 µg ( test ) compare formoterol Aerolizer 12 µg ( reference ) .</brief_summary>
	<brief_title>Relative Potency Formoterol Novolizer® 12 µg Compared Formoterol Aerolizer® 12 µg</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Male female patient age 18 60 year ( inclusive ) . 2 . Patients asthma indicated history asthma symptom airway hyperresponsiveness methacholine provocation concentration methacholine cause 20 % decrease FEV1 ( PC20 ) ≤8 mg/ml Visit 1 . 3 . Patients stable asthma condition baseline force expiratory volume first second ( FEV1 ) ≥70 % predict first visit . 4 . The PC20 methacholine increase least 4fold inhale 24 μg formoterol Aerolizer ( 2 application 12 μg ) Visit 2 . 5 . Able taught correct inhalation technique device screen . 1 . Known hypersensitivity formoterol , lactose , methacholine . 2 . History lifethreatening asthma last three year . 3 . Major malignancy include pheochromocytoma within last 5 year . Exception consider malignancy resolve judged investigator . 4 . Pregnancy , breastfeeding , plan pregnancy study , woman childbearing potential use adequate contraception . These method include total abstinence ( sexual intercourse ) , oral contraceptive , intrauterine device ( IUD ) , etonogestrel implant ( Implanon ) , medroxyprogesterone acetate injection ( DepoProvera shot ) . If one use , use contraceptive foam condom recommend . Lack suitability study : 5 . Screening visit 2 postpone repeatedly . 6 . Evidence respiratory tract infection within 4 week study ( screen visit 1 ) . 7 . Seasonal episodic exposure allergen occupational chemical sensitizer likely vary symptom presentation severity course study ( e.g . ragweed sensitive patient Iowa AugOct ) . This apply patient well control therapy . 8 . History nonreversible pulmonary disease ; chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , pulmonary fibrosis . 9 . History severe cardiovascular , renal , neurologic , liver endocrine dysfunction ( patient wellcontrolled hypertension , hypercholesterolemia , thyroid disease diabetes may include medication disease affect methacholine challenge formoterol metabolism ) . 10 . History hemophilia coagulation disease . 11 . Electrocardiogram ( ECG ) abnormalities clinical relevance , particular abnormal prolongation QTinterval ( QTc accord Bazett woman ≥450 msec , men ≥430 msec ) . 12 . Potassium level lower limit laboratory normal range plus 0.3 mmol/l safety margin . 13 . Exacerbation bronchial asthma require emergency department visit hospitalization last 3 month prior study . 14 . Prior concomitant treatment systemic glucocorticosteroids last 3 month ( short course oral corticosteroid asthma permissible &lt; 10 day least 30 day pass ) . 15 . Use longacting ß2agonists last 3 week first methacholine challenge study 16 . Change dosage controller therapy ( inhaled glucocorticosteroids , leukotriene modifier , slowrelease theophylline ) last 3 week first methacholine challenge study . 17 . Use shortacting ß2agonists thrice week previous month . 18 . Inability temporary withhold follow medications/substances lung function test : shortacting ß2agonists shortacting anticholinergic least 6 hour , regular longacting ß2agonists least 3 week , longacting anticholinergic least 36 hour , inhaled glucocorticosteroids least 2 hour Disodium cromoglycate ( DSCG ) least 24 hour , slow release theophylline least 48 hour , rapid release theophylline least 24 hour , caffeine least 4 hour 19 . Patients aspirin induced bronchospasm . 20 . Any treatment ß2antagonists ( include eye drop ) . 21 . Noncooperative patient , inability perform outcome measurement correctly . 22 . Inability measure PC20 methacholine 24 μg formoterol Aerolizer ( PC20 &gt; 128 mg/ml ) . 23 . Current smoker regular smoker last 12 month 10 packyear history . 24 . Drug alcohol abuse would interfere patient 's proper completion protocol assignment . Administrative reason : 25 . Participation another clinical study within 1 month prior study 26 . Lack ability willingness give inform consent . 27 . Lack willingness personal study relate data collect , archive transmit accord protocol . 28 . Personnel involve plan conduct study . 29 . Anticipated nonavailability study visits/procedures .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>